LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 35

Search options

  1. Article ; Online: Drug-induced suppression of HbA1C in dermatology.

    Parker, Eva Rawlings / Dewan, Anna K

    Journal of the American Academy of Dermatology

    2023  

    Language English
    Publishing date 2023-04-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2023.04.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Business Education in Dermatology Residency: A Survey of Program Directors.

    Patrinely, James Randall / Dewan, Anna K

    Cutis

    2021  Volume 108, Issue 2, Page(s) E17–E19

    Abstract: With the rising cost of health care in the United States and an increasingly competitive market, dermatology residents would benefit from business training. We constructed an 8-part questionnaire for dermatology program directors (PDs) to determine the ... ...

    Abstract With the rising cost of health care in the United States and an increasingly competitive market, dermatology residents would benefit from business training. We constructed an 8-part questionnaire for dermatology program directors (PDs) to determine the current perceptions of and resources available for business education. Of the 139 surveys distributed, 35 were completed (25.2%). Approximately one half of the respondents said their programs offered business training, primarily through seminars or lectures. Most PDs felt business education during residency was important and that programs should implement more training. The most important topics identified for inclusion in a business curriculum were economics or finance, management, and health care policy or government. Our survey identified a gap between the perceived importance and current supply of business education during dermatology residency training. Future efforts should aim to develop a standardized, dermatology-specific curriculum that is readily available to all programs and residents.
    MeSH term(s) Curriculum ; Dermatology/education ; Education, Medical, Graduate ; Humans ; Internship and Residency ; Surveys and Questionnaires ; United States
    Language English
    Publishing date 2021-11-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 391840-3
    ISSN 2326-6929 ; 0011-4162 ; 0151-9522
    ISSN (online) 2326-6929
    ISSN 0011-4162 ; 0151-9522
    DOI 10.12788/cutis.0331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The modern dermatology program director: A cross-sectional study on personal and professional characteristics.

    Patrinely, J Randall / Dewan, Anna K

    Journal of the American Academy of Dermatology

    2020  Volume 84, Issue 5, Page(s) 1419–1421

    MeSH term(s) Adult ; Cross-Sectional Studies ; Dermatology/education ; Dermatology/organization & administration ; Dermatology/statistics & numerical data ; Educational Status ; Female ; Humans ; Internship and Residency/organization & administration ; Internship and Residency/statistics & numerical data ; Leadership ; Male ; Middle Aged ; Sexism/statistics & numerical data ; United States
    Language English
    Publishing date 2020-06-03
    Publishing country United States
    Document type Letter
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2020.05.140
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Kaposi Sarcoma Updates.

    Etemad, Shervin A / Dewan, Anna K

    Dermatologic clinics

    2019  Volume 37, Issue 4, Page(s) 505–517

    Abstract: Kaposi sarcoma (KS) is an angioproliferative mesenchymal neoplasm caused by Kaposi sarcoma-related herpesvirus. This review outlines our current understanding of the epidemiology, pathogenesis, clinical presentation, and staging for this disease. Recent ... ...

    Abstract Kaposi sarcoma (KS) is an angioproliferative mesenchymal neoplasm caused by Kaposi sarcoma-related herpesvirus. This review outlines our current understanding of the epidemiology, pathogenesis, clinical presentation, and staging for this disease. Recent research has informed a more comprehensive understanding of the epidemiology of KS in the post-antiretroviral therapy era, and highlights the continued need to better characterize the African endemic subtype. Advances in clinical oncology, including checkpoint inhibitors and new skin-directed therapies, have translated into exciting new developments for the future of KS treatment options.
    MeSH term(s) Acquired Immunodeficiency Syndrome/drug therapy ; Acquired Immunodeficiency Syndrome/epidemiology ; Administration, Cutaneous ; Anti-HIV Agents/therapeutic use ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antiviral Agents/therapeutic use ; Brachytherapy ; Cryosurgery ; Herpesviridae Infections/drug therapy ; Herpesviridae Infections/epidemiology ; Herpesviridae Infections/pathology ; Herpesvirus 8, Human ; Humans ; Immunosuppressive Agents/adverse effects ; Injections, Intralesional ; Laser Therapy ; Radiotherapy ; Sarcoma, Kaposi/epidemiology ; Sarcoma, Kaposi/pathology ; Sarcoma, Kaposi/therapy ; Sarcoma, Kaposi/virology ; Skin Neoplasms/epidemiology ; Skin Neoplasms/pathology ; Skin Neoplasms/therapy ; Skin Neoplasms/virology
    Chemical Substances Anti-HIV Agents ; Antineoplastic Agents ; Antineoplastic Agents, Immunological ; Antiviral Agents ; Immunosuppressive Agents
    Language English
    Publishing date 2019-07-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 82798-8
    ISSN 1558-0520 ; 0733-8635
    ISSN (online) 1558-0520
    ISSN 0733-8635
    DOI 10.1016/j.det.2019.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models.

    Park, Benjamin C / Stone, Cosby A / Dewan, Anna K / Johnson, Douglas B

    Immunology and allergy clinics of North America

    2022  Volume 42, Issue 2, Page(s) 285–305

    Abstract: Immune checkpoint inhibitors (ICI) are a major class of cancer therapeutics that may cause durable responses in a growing proportion of patients with metastatic cancer. These agents remove negative regulators on T cells and may cause autoimmunelike ... ...

    Abstract Immune checkpoint inhibitors (ICI) are a major class of cancer therapeutics that may cause durable responses in a growing proportion of patients with metastatic cancer. These agents remove negative regulators on T cells and may cause autoimmunelike toxicities that affect all organ systems. Monoclonal antibodies are much less commonly associated with traditional hypersensitivity reactions. Herein, we discuss the pathophysiology, clinical presentation, and management of toxicities of ICI and discuss their broader context within drug hypersensitivity.
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Humans ; Hypersensitivity/diagnosis ; Hypersensitivity/etiology ; Hypersensitivity/therapy ; Immune Checkpoint Inhibitors/adverse effects ; Immunotherapy/adverse effects ; Neoplasms/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-03-31
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 92606-1
    ISSN 1557-8607 ; 0889-8561
    ISSN (online) 1557-8607
    ISSN 0889-8561
    DOI 10.1016/j.iac.2021.12.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma.

    Goodman, Rachel S / Justice, Joy / Gardner, Laura J / Singh, Reena / Dewan, Anna K / Johnson, Douglas B

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 192, Page(s) 113255

    MeSH term(s) Humans ; Melanoma/drug therapy ; Skin Neoplasms/drug therapy ; Melanoma, Cutaneous Malignant
    Language English
    Publishing date 2023-08-16
    Publishing country England
    Document type Case Reports ; Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.113255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.

    Patrinely, James Randall / Dewan, Anna K / Johnson, Douglas B

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

    2020  Volume 34, Issue 4, Page(s) 495–503

    Abstract: Skin cancers remain the most common group of cancers globally, and the incidence continues to rise. Although localized skin cancers tend to have excellent outcomes following surgical excisions, the less common cases that become surgically unresectable or ...

    Abstract Skin cancers remain the most common group of cancers globally, and the incidence continues to rise. Although localized skin cancers tend to have excellent outcomes following surgical excisions, the less common cases that become surgically unresectable or metastatic have been associated with poor prognosis and suboptimal treatment responses to cytotoxic chemotherapy. Development of monoclonal antibodies to programmed cell death-1 receptor and its ligand (PD-1/PD-L1) have transformed the management of metastatic melanoma, squamous cell carcinoma, and Merkel cell carcinoma. These agents, as monotherapies, are associated with response rates of approximately 40-60%, many of which persist durably. Further efficacy is observed with combination immunotherapy in advanced melanoma. Early reports suggest similar activity in locally advanced or metastatic basal cell carcinoma. In this review, we describe common molecular features of skin cancers that may render them particularly susceptible to anti-PD-1/PD-L1 and detail results from key clinical trials of these agents across skin cancers. Overall, the superior response rates of skin cancer to anti-PD-1/PD-L1 compared with other solid tumor types are likely due, at least in part, to a high mutational burden and, in Merkel cell carcinoma, viral etiology. Although melanoma has been rigorously studied in the setting of anti-PD-1/PD-L1 treatment, more research is needed for the other skin cancer types to establish toxicity profiles, responses, and quality-of-life outcomes.
    MeSH term(s) Antineoplastic Agents, Immunological/therapeutic use ; B7-H1 Antigen/chemistry ; B7-H1 Antigen/therapeutic use ; Humans ; Immunotherapy ; Melanoma/drug therapy ; Melanoma/genetics ; Programmed Cell Death 1 Receptor/chemistry ; Programmed Cell Death 1 Receptor/metabolism ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics
    Chemical Substances Antineoplastic Agents, Immunological ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2020-02-01
    Publishing country New Zealand
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1364202-9
    ISSN 1179-190X ; 1173-8804
    ISSN (online) 1179-190X
    ISSN 1173-8804
    DOI 10.1007/s40259-020-00428-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

    Park, Benjamin C / Jung, Seungyeon / Chen, Steven T / Dewan, Anna K / Johnson, Douglas B

    American journal of clinical dermatology

    2022  Volume 23, Issue 5, Page(s) 707–717

    Abstract: Immune checkpoint inhibitors have emerged as a new paradigm in oncologic care for many malignancies. However, nonspecific immune activation has led to "collateral damage" in the form of immune-related adverse events, with skin being a commonly affected ... ...

    Abstract Immune checkpoint inhibitors have emerged as a new paradigm in oncologic care for many malignancies. However, nonspecific immune activation has led to "collateral damage" in the form of immune-related adverse events, with skin being a commonly affected organ. Cutaneous immune-related adverse events include a wide spectrum of clinical presentations and challenging considerations, often necessitating dermatology referral to support diagnosis and management, particularly for atypical presentations or more severe, cutaneous immune-related adverse events that may require specialized dermatologic evaluations including biopsy and histopathology. Close collaborations between oncologists and dermatologists may optimize clinical decision making in the following challenging management settings: non-steroidal therapies for corticosteroid-refractory, cutaneous immune-related adverse events, immune checkpoint inhibitor rechallenge, balancing cutaneous immune-related adverse events and treatments, and immune checkpoint inhibitors in patients with pre-existing autoimmune disease, skin conditions, and organ transplants. These complex clinical decisions that often lack rigorous data should be made in close collaboration with dermatologists to minimize unnecessary morbidity and mortality. This article provides a review of approaches to challenging dermatologic considerations associated with immune checkpoint inhibitor therapies.
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/adverse effects ; Medical Oncology ; Neoplasms/drug therapy ; Skin/pathology ; Skin Diseases/chemically induced ; Skin Diseases/diagnosis ; Skin Diseases/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-06-16
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 1502476-3
    ISSN 1179-1888 ; 1175-0561
    ISSN (online) 1179-1888
    ISSN 1175-0561
    DOI 10.1007/s40257-022-00706-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Cost assessment in melanoma clinical trials: A cross-sectional study.

    Goodman, Rachel S / Garner, Desmond C / Koester, Stefan / Patrinely, J Randall / Dewan, Anna K / Johnson, Douglas B

    JAAD international

    2023  Volume 12, Page(s) 139–141

    Language English
    Publishing date 2023-05-26
    Publishing country United States
    Document type Journal Article
    ISSN 2666-3287
    ISSN (online) 2666-3287
    DOI 10.1016/j.jdin.2023.05.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline.

    Larocca, Cecilia A / Fay, Christopher J / Hirner, Jesse P / Meyerhardt, Jeffrey A / Cleary, James M / Dewan, Anna K / LeBoeuf, Nicole R

    JAMA dermatology

    2023  Volume 159, Issue 10, Page(s) 1136–1139

    MeSH term(s) Humans ; Pentoxifylline/therapeutic use ; Neoplasms ; Stomatitis, Aphthous ; Behcet Syndrome ; Skin
    Chemical Substances Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2023-08-17
    Publishing country United States
    Document type Letter
    ZDB-ID 2701761-8
    ISSN 2168-6084 ; 2168-6068
    ISSN (online) 2168-6084
    ISSN 2168-6068
    DOI 10.1001/jamadermatol.2023.2649
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top